MBIOMUSTANG BIO, INC.

Nasdaq mustangbio.com


$ 0.20 $ -0.01 (-4.82 %)    

Friday, 31-May-2024 15:59:46 EDT
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 0.2012
$ 0.22
$ 0.00 x 0
$ 0.00 x 0
$ 0.20 - $ 0.22
$ 0.16 - $ 8.17
6,256,552
na
2.26M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-11-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-24-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-18-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-29-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 03-31-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-mustang-bio-maintains-2-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Mustang Bio (NASDAQ:MBIO) with a Buy and maintains $2 price target.

 hc-wainwright--co-maintains-buy-on-mustang-bio-adjusts-price-target-to-2

HC Wainwright & Co. analyst Joseph Pantginis maintains Mustang Bio (NASDAQ:MBIO) with a Buy, adjusts target to $2 from $25.

 reported-earlier-mustang-bio-prices-4m-public-offering-of-16877638-shares-of-common-stock-at-0237share

Mustang Bio announced the pricing of a public offering of an aggregate of 16,877,638 shares of its common stock (or common stoc...

 mustang-bio-files-for-offering-of-up-to-156m-shares-of-common-stock-together-with-accompanying-warrants

-SEC Filing

 mustang-bio-inc-approved-a-reduction-of-its-workforce-by-81-of-its-employee-base-workforce-reduction-will-take-place-primarily-in-april-2024-expected-to-be-substantially-completed-in-q2-of-2024-continue-to-evaluate-all-strategic-and-other-alternatives-related-to-business

- SEC Filing

 mustang-bio-expands-car-t-cell-therapy-platform-expansion-into-autoimmune-diseases

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy ...

 mustang-bio-reports-fy23-eps-of-600-vs-1009-yoy-and-recent-corporate-highlights

Financial Results: As of December 31, 2023, Mustang's cash and cash equivalents and restricted cash totaled $7.0 million...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION